{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:40:10Z","timestamp":1782895210664,"version":"3.54.5"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Specialized pro-resolving lipid mediators are involved in post-stroke neuroinflammation, but their relevance in large artery atherosclerotic (LAA) stroke, particularly in relation to diabetes duration, remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center retrospective study, 175 patients with LAA stroke were enrolled. Serum lipoxin A4 (LXA4), leukotriene B4 (LTB4), and resolvin D2 (RvD2) were measured within 72\u202fh of stroke onset. Functional outcome at 3\u202fmonths was assessed using the modified Rankin Scale. Analyses were stratified by type 2 diabetes mellitus (T2DM) status and diabetes duration (&amp;lt;5 vs. \u22655\u202fyears). Logistic regression and linear support vector machine models were used in exploratory analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 175 patients, 130 had a favorable outcome and 45 a poor outcome. LXA4 levels were higher in the favorable-outcome group, although the difference was not significant. No significant differences in LXA4, LTB4, or RvD2 were observed between patients with and without T2DM. In contrast, within the T2DM subgroup, patients with a diabetes duration of \u22655\u202fyears showed higher LXA4 and LTB4 levels and a lower RvD2\/LTB4 ratio than those with a duration of &amp;lt;5\u202fyears. Diabetes duration correlated positively with both LXA4 and LTB4. In exploratory machine learning analyses, LXA4 was consistently retained, and model performance declined after its removal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings are exploratory. LAA stroke was associated with diabetes duration-related remodeling of specialized pro-resolving lipid mediator profiles. Compared with diabetes status alone, diabetes duration may better reflect metabolic-inflammatory heterogeneity. These findings are exploratory; LXA4 did not demonstrate a statistically significant association with functional outcome, and no independent prognostic value has been established. LXA4 may represent a candidate signaling molecule warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1841577","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:31:41Z","timestamp":1782891101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diabetes-duration-related shifts in inflammation-resolving lipid mediator signatures and their association with 3-month functional outcome in large artery atherosclerotic stroke"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei-Meng","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Hebei University, Clinical Medical College, Hebei University","place":["Baoding, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Liang","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Hebei University, Clinical Medical College, Hebei University","place":["Baoding, Hebei, China"]},{"name":"Department of Neurosurgery, Baoding First Central Hospital","place":["Baoding, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Xu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Hebei Provincial Mental Health Center, The Sixth Clinical Medical College Hebei University","place":["Baoding, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Chao","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Baoding First Central Hospital","place":["Baoding, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Affiliated Hospital of Hebei University, Clinical Medical College, Hebei University","place":["Baoding, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.cell.2022.04.004","article-title":"Atherosclerosis: recent developments","volume":"185","author":"Bj\u00f6rkegren","year":"2022","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.5114\/fn.2021.112007","article-title":"Risk factors for ischemic stroke: differences between cerebral small vessel and large artery atherosclerosis aetiologies","volume":"59","author":"Shi","year":"2021","journal-title":"Folia Neuropathol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"C135","DOI":"10.1152\/ajpcell.00136.2018","article-title":"Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke","volume":"316","author":"Yang","year":"2019","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.diabres.2005.02.001","article-title":"Diabetes worsens the outcome of acute ischemic stroke","volume":"69","author":"Kaarisalo","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5853\/jos.2022.02306","article-title":"Diabetes and stroke: what are the connections?","volume":"25","author":"Mosenzon","year":"2023","journal-title":"J Stroke"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/ijms26031094","article-title":"Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications","volume":"26","author":"M\u0142ynarska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/biom12111712","article-title":"Receptor for advanced glycation end product, organ crosstalk, and pathomechanism targets for comprehensive molecular therapeutics in diabetic ischemic stroke","volume":"12","author":"Rao","year":"2022","journal-title":"Biomolecules"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00281-009-0144-9","article-title":"Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis","volume":"31","author":"Walcher","year":"2009","journal-title":"Semin Immunopathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1515\/CCLM.2005.192","article-title":"Homocysteine, type 2 diabetes mellitus, and cognitive performance: the Maine-Syracuse study","volume":"43","author":"Robbins","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41569-023-00984-x","article-title":"Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease","volume":"21","author":"Fredman","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1161\/STROKEAHA.124.049871","article-title":"Specialized pro-resolving lipid mediator profiles and stroke outcome heterogeneity in large artery atherosclerotic stroke: a prospective cohort analysis","volume":"56","author":"Hao","year":"2025","journal-title":"Stroke"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12974-025-03412-x","article-title":"Lipid mediator profiling in diabetic ischemic stroke reveals distinct pro-resolving deficits linked to worse functional outcome","volume":"22","author":"Miao","year":"2025","journal-title":"J Neuroinflammation"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1161\/CIRCRESAHA.116.308398","article-title":"Stroke risk factors, genetics, and prevention","volume":"120","author":"Boehme","year":"2017","journal-title":"Circ Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1172\/jci97943","article-title":"Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J Clin Invest"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.3390\/ijms22084207","article-title":"Could lipoxins represent a new standard in ischemic stroke treatment?","volume":"22","author":"TU\u0142OWIECKA","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3233\/JAD-201050","article-title":"Reduced levels of plasma lipoxin A4 are associated with post-stroke cognitive impairment","volume":"79","author":"Wang","year":"2021","journal-title":"J Alzheimer's Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"6657646","DOI":"10.1155\/2021\/6657646","article-title":"Plasma resolvin D2 to leukotriene B(4) ratio is reduced in diabetic patients with ischemic stroke and related to prognosis","volume":"2021","author":"Miao","year":"2021","journal-title":"Biomed Res Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1161\/STROKEAHA.111.641381","article-title":"Duration of diabetes and risk of ischemic stroke: the northern Manhattan study","volume":"43","author":"Banerjee","year":"2012","journal-title":"Stroke"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e2317","DOI":"10.1210\/clinem\/dgae092","article-title":"Diabetes duration, cholesterol levels, and risk of cardiovascular diseases in individuals with type 2 diabetes","volume":"109","author":"Kim","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12902-024-01731-0","article-title":"Prevalence, patterns, and determinants of vascular complications of type 2 diabetes in a teaching hospital in Addis Ababa, Ethiopia: a retrospective study","volume":"24","author":"Solela","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1100\/tsw.2007.186","article-title":"Lipoxin receptors","volume":"7","author":"Romano","year":"2007","journal-title":"Sci World J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"917974","DOI":"10.3389\/fimmu.2022.917974","article-title":"Plasma lipid mediators associate with clinical outcome after successful endovascular thrombectomy in patients with acute ischemic stroke","volume":"13","author":"Hao","year":"2022","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.freeradbiomed.2022.06.231","article-title":"Resolution of inflammation is disturbed in acute ischemic stroke with diabetes mellitus and rescued by resolvin D2 treatment","volume":"188","author":"Tang","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M18-1377","article-title":"PROBAST: a tool to assess risk of Bias and applicability of prediction model studies: explanation and elaboration","volume":"170","author":"Moons","year":"2019","journal-title":"Ann Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1841577\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:31:42Z","timestamp":1782891102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1841577\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":26,"alternative-id":["10.3389\/fneur.2026.1841577"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1841577","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1841577"}}